The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials

Expert Opinion on Investigational Drugs

Volumn 20, Issue 12, 2011, Pages 1677-1684

  Varkaris, Andreas ^a   Corn, Paul G ^a   Gaur, Sanchaika ^a,b   Dayyani, Farshid ^a   Logothetis, Christopher J ^a   Gallick, Gary E ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

C Met; HGF; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BMS 777607; CABOZANTINIB; CRIZOTINIB; DASATINIB; FORETINIB; PROTEIN INHIBITOR; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB; UNCLASSIFIED DRUG; XL 184;

ADVANCED CANCER; CANCER GROWTH; CANCER INVASION; CLINICAL RESEARCH; DRUG TARGETING; METASTASIS; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG DESIGN; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 81555228393     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.631523     Document Type: Review

References (61)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Available from: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=840
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36
3. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83 (Pubitemid 30323983)
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12 (Pubitemid 39315317)
5. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005
6. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54
7. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48
8. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997-1011
9. Giordano S, Di Renzo MF, Narsimhan RP, et al. Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene 1989;4:1383-8 (Pubitemid 19273394)
10. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25 (Pubitemid 37493640)
11. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met protooncogene product. Science 1991;251:802-4 (Pubitemid 21926175)
12. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987;327:239-42 (Pubitemid 17071053)
13. Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 1990;111:2097-108
14. Park SI, Zhang J, Phillips KA, et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008;68:3323-33
15. Araujo JC, Poblenz A, Corn P, et al. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cellinduced osteoclast formation. Cancer Biol Ther 2009;8:2153-9
16. Jensen AR, David SY, Liao C, et al. Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res 2011;17:3112-22
17. Ghatak S, Hascall VC, Markwald RR, Misra S. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor. J Biol Chem 2010;285:19821-32
18. Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001;107:643-54 (Pubitemid 34014865)
19. Chen SY, Chen HC. Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol Cell Biol 2006;26:5155-67
20. Xu L, Nilsson MB, Saintigny P, et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 2010;29:2616-27
21. Dulak AM, Gubish CT, Stabile LP, et al. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011;30:3625-35
22. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2010;16:37-45
23. Kim S, Lee UJ, Kim MN, et al. MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem 2008;283:18158-66
24. Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009;275:44-53
25. Hu G, Chen D, Li X, et al. miR-133b regulates the MET proto-oncogene and inhibits the growth of colorectal cancer cells in vitro and in vivo. Cancer Biol Ther 2010;10:190-7
26. Cai KM, Bao XL, Kong XH, et al. Hsa-miR-34c suppresses growth and invasion of human laryngeal carcinoma cells via targeting c-Met. Int J Mol Med 2010;25:565-71
27. Migliore C, Petrelli A, Ghiso E, et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res 2008;68:10128-36
28. Salvi A, Sabelli C, Moncini S, et al. MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells. FEBS J 2009;276:2966-82
29. Gaur S, Gallick EG. Elucidating the role of c-Met overexpression and its regulation in prostate cancer progression. Second AACR International Conference on Frontiers in Basic Cancer Research. Poster Session; 14-18 September 2011; in San Francisco, CA
30. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002;60:1113-17 (Pubitemid 35447590)
31. Colombel M, Eaton CL, Hamdy F, et al. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate 2011;doi: 10.1002/pros.21473 [Epub ahead of print]
32. van Leenders GJ, Gage WR, Hicks JL, et al. Intermediate cells in human prostate epithelium are enrichedin proliferative inflammatory atrophy. Am J Pathol 2003;162:1529-37 (Pubitemid 36512835)
33. Verras M, Lee J, Xue H, et al. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007;67:967-75
34. Humphrey PA, Zhu X, Zarnegar R, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-96
35. Pisters LL, Troncoso P, Zhau HE, et al. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-8
36. Yasuda K, Nagakawa O, Akashi T, et al. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer. Prostate 2009;69:346-51
37. Gupta A, Karakiewicz PI, Roehrborn CG, et al. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res 2008;14:7385-90
38. Russo AL, Jedlicka K, Wernick M, et al. Urine analysis and protein networking identify met as a marker of metastatic prostate cancer. Clin Cancer Res 2009;15:4292-8
39. Maeda A, Nakashiro K, Hara S, et al. Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochem Biophys Res Commun 2006;347:1158-65 (Pubitemid 44118235)
40. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003;3:347-61 (Pubitemid 38340304)
41. Scarpino S, Cancellario d'Alena F, Di Napoli A, et al. Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 2004;202:352-8 (Pubitemid 38325245)
42. Fan S, Ma YX, Wang JA, et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene 2000;19:2212-23 (Pubitemid 30307187)
43. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010;70:10090-100
44. Sen B, Peng S, Saigal B, et al. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin Cancer Res 2011;17:514-24
45. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43 (Pubitemid 46799492)
46. Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther 2010;9:1554-61
47. Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors. Available from: http://clinicaltrials.gov/ct2/show/ NCT00605618
48. Tu WH, Zhu C, Clark C, et al. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 2010;10:556
49. A Phase 1 Absolute Bioavailability Study For Oral crizotinib In Healthy Volunteers. Available from: http://clinicaltrials.gov/ct2/results? term=crizotinib
50. Youzhi Li, Chen D, Zhou W, et al. Broad Spectrum anti-cancer activity of ARQ 197, a highly selective oral c-Met Inhibitor, in multiple xenograft models [abstract 2216]. 2007 AACR Annual Meeting
51. Adjei AA, Schwartz B, Garmey E. Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers. Oncologist 2011;16:788-99
52. Yap TA, Olmos D, Brunetto AT, et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29:1271-9
53. Qian F, Engst S, Yamaguchi K, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009;69:8009-16
54. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010;16:3507-16
55. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007;13:6735-42 (Pubitemid 350206811)
56. Burgess TL, Sun J, Meyer S, et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther 2010;9:400-9
57. AMG 102 in Combination with Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00770848
58. Smith DC, Spira A, Greve JD, et al. Phase 2 Study of XL184 in a Cohort of Patients with Castration Resistant Prostate Cancer (CRPC) and Measurable Soft Tissue Disease. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 16-19 November 2010; Berlin, Germany
59. Smith DC, Smith MR, Small EJ, et al. Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. J Clin Oncol 2011;29(Suppl 7):abstract 127
60. Hussain MR, Smith C, Sweeney PG, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial. J Clin Oncol 2011;29(Suppl):abstract 4516
61. Logothetis CJ, Navone NM, Lin SH. Understanding the biology of bone metastases: key to the effective treatment of prostate cancer. Clin Cancer Res 2008;14:1599-602 (Pubitemid 351469442)